Introduction {#s1}
============

Fever is the main complaint among pediatric emergency services ([@B1]). In only 15% (IQR 8·0--23·2%) a serious bacterial infection (SBI) is diagnosed with pneumonia and urinary tract infection (UTI) being the most prevalent ([@B2], [@B3]).

In contrast to the above, high antibiotic prescriptions are observed in febrile children ([@B4], [@B5]). Guidelines, or new diagnostic approaches have shown to effectively reduce antibiotic prescriptions in primary care ([@B6]--[@B9]). This is important because unnecessary antibiotic use increases antibiotic resistance ([@B10], [@B11]). In contrast to hospital based studies or primary care settings ([@B11]--[@B15]), few studies have been published in emergency department (ED) settings nor do we have valid estimates of potential benefits of antibiotic reducing interventions. Therefore our primary study aim is to assess antibiotic prescriptions for febrile children visiting the emergency department and their determinants. Secondary, we aim to investigate potential interventions that have been proven to be effective in the ED.

Methods {#s2}
=======

Study characteristics
---------------------

All descriptive and interventional studies published in 2000--2017 reporting on antibiotic use in children (age under 18) with fever in the emergency department were eligible for this review.

Search strategy
---------------

We searched Embase, Medline (OvidSP), Web-of-science, Scopus, Cinahl, Cochrane, PubMed publisher, and Google scholar for the (analogs of) keywords: fever, antibiotics, emergency department, children and antibiotic prescription. Initially search was performed in 2015 and updated in October 2017 (Supplementary Material [1](#SM1){ref-type="supplementary-material"}). References were checked for additional articles to be included.

Inclusion
---------

A screening by title/abstract resulted in potential eligible articles that underwent full text review. Two authors reviewed all articles; any discrepancies were solved by oral agreement between authors. -- Setting: Emergency department; if mixed settings, at least 30% (50 patients minimum) of the population needed to be admitted to the ED.-- Design: observational studies and randomized controlled trials with a minimum of 50 participants.-- Outcome: the studies had to report the number or percentage of antibiotics prescribed.-- Population: participants under the age of 18; if mixed ages, at least 20% of the population needed to be \<18 years (with a minimum of 50) or age specific antibiotic prescriptions had to be presented. Studies on children with specific comorbidities only were excluded.-- Fever: at least 30% of all included children needed to have fever or the reason of visit was (reported) fever.

Quality assessment of included articles
---------------------------------------

To compare the risk-of-bias of all these different study designs all articles were assessed using the MINORS criteria ([@B16]). Zero points were given for the item if not reported, one point if reported but insufficient and two points if reported and sufficient. As loss to follow-up was not applicable, due to emergency setting, we have let this particular item out of consideration; the maximum score for studies is 14 or 22 for respectively non-comparative and comparative studies. A maximum score on the MINORS criteria was needed to receive the status of a low risk of bias study (A) ([@B17]). For the final quality assessment we additionally used the sample size and the primary outcome. A high quality study was defined by status low risk of bias (A) on the MINORS, antibiotic prescription being the primary outcome and a sample size of at least 500 children. Two reviewers (EV and RO) have independently assessed all included studies. Supplementary Material [2](#SM1){ref-type="supplementary-material"} contains the complete quality assessment.

Data extraction and analysis
----------------------------

Extracted data included: Author, year, and country of publishing, study design, inclusion criteria, primary outcome, median (or mean when median not available) age, number of included children. Aiming to invest determinants of antibiotic prescription, we additionally extracted (if available): diagnosis, type of antibiotics, type of physicians, and type of intervention.

Due to heterogeneity in participants, outcome measures, interventions and study designs, no statistical pooling but a qualitative analysis was performed ([@B18]). Results are presented for the 5 main diagnosis, i.e., fever, AOM, pneumonia, other respiratory tract infections (RTI other) and UTI, with a minimum of 50 cases per diagnostic group required.

Results {#s3}
=======

Literature search
-----------------

We obtained 837 articles by literature search. Screening the full text articles excluded 97 out of 151, which leaves 52 articles for data extraction. Two additional studies were included by reference check of included studies (Figure [1](#F1){ref-type="fig"}).

![Flowchart of the study selection and exclusion.](fped-06-00260-g0001){#F1}

Characteristics of the included studies
---------------------------------------

The study characteristics are presented in Table [1](#T1){ref-type="table"} for the included 54 studies. Most studies come from the US (*n* = 32, 59%), 16 others came from Europe, and 6 others from Canada (*n* = 3) ([@B33], [@B36], [@B49]), Australia (*n* = 2) ([@B3]), and Israel (*n* = 1) ([@B26]). The size of the studied population varied between 72 and 266.000 participants (median = 391). Most studies included children up to 36 months (*n* = 14, 25%) or all ages \< 18 year (*n* = 18, 32%). Antibiotic prescription was the primary outcome in 33 studies (59%). Quality and feasibility assessment of the included studies (Supplementary Material [2](#SM1){ref-type="supplementary-material"}).

###### 

Characteristics of descriptive studies about antibiotic prescription.

  **Reference, Country**                                             **Study design**   **Age group/inclusion**   **Median (IQR) or Mean age ± SD**                     **Inclusion criteria**                                                  **N children included**   **Quality**
  ------------------------------------------------------------------ ------------------ ------------------------- ----------------------------------------------------- ----------------------------------------------------------------------- ------------------------- -------------
  Ahmed et al. ([@B19]), US                                          CSp                0--18 years               NR                                                    URTI                                                                    321                       Low
  Angoulvant et al. ([@B20]), France                                 CR                 \<18 years                17 months (7--40)                                     ARTI                                                                    53.055                    High
  Aronson et al. ([@B21]), US                                        CSr                29--56 days               46 days (37--53)                                      Fever                                                                   1626                      High
                                                                                                                  45 days (37--53)                                                                                                                                        
  Ayanruoh et al. ([@B22]), US                                       CSr                3--18 years               NR                                                    Clinical diagnosis of pharyngitis                                       8280                      Low
  Benin et al. ([@B23]), US                                          CSr                3--18 years               8.7 years (6--13)                                     Diagnosis pharyngitis                                                   391                       Moderate
  Benito-Fernández et al. ([@B24]), Spain                            CP                 0--36 months              6.86 months ± 6.3[°](#TN2){ref-type="table-fn"}       Fever without source                                                    206                       Low
                                                                                                                  6.55 months ± 6.8[°](#TN2){ref-type="table-fn"}                                                                                                         
  Blaschke et al. ([@B25]) US^◇^                                     CSr                All ages                  53% \< 18 years                                       Influenza                                                               58                        Low
  Brauner et al. ([@B26]), Israel                                    CCr                3--36 months              NR                                                    Fever and complete blood count                                          292                       Moderate
  Bonner et al. ([@B27]), US                                         RCT                2 months−21 years         NR                                                    Influenza                                                               202                       Moderate
  Bustinduy et al. ([@B28]), UK                                      CP                 \<16 years                2 years (1--4 years)                                  Fever or reported fever                                                 1097                      Moderate
  Chao et al. ([@B29]), US                                           RCT                2--12 years               5.01 years (3.67--6.68)                               AOM                                                                     206                       Moderate
                                                                                                                  3.73 years (2.82--5.75)                                                                                                                                 
  Craig et al. ([@B3]), Australia                                    CP                 \<6 years                 ± 60% \< 24 months                                    Fever                                                                   15.781                    High
  Coco et al. ([@B30]), US                                           CSr                \<12 years                ± 2 years[^\*^](#TN1){ref-type="table-fn"}            AOM                                                                     8325                      High
  Colvin et al. ([@B31]), US                                         CP                 2--36 months              8.0 months                                            Fever without source [¥](#TN3){ref-type="table-fn"}                     75                        Low
  Copp et al. ([@B32]), US                                           CSr                \<18 years                ±6 years[^\*^](#TN1){ref-type="table-fn"}             UTI                                                                     1828 (36% in ED)          Low
  Doan et al. ([@B33]), Canada                                       RCT                3--36 months              15 months (3--36)                                     Acue respiratory symptoms                                               199                       Moderate
                                                                                                                  14 months (4--34)                                                                                                                                       
  Fischer et al. ([@B34]), US                                        CP                 2--18 years               68% 2--6 years                                        AOM                                                                     144                       Low
  Galetto Lacour et al. ([@B35]), Switzerland                        CP                 7 days −36 months         11 months[^\*^](#TN1){ref-type="table-fn"}            Fever without source [¥](#TN3){ref-type="table-fn"}                     124                       Moderate
  Galetto-Lacour et al. ([@B35]), Switzerland                        CP                 7 days −36 months         7.2 months (0.4--31.1)                                Fever without source [¥](#TN3){ref-type="table-fn"}                     99                        Low
                                                                                                                  9.7 months (0.7--34)                                                                                                                                    
  Goldman et al. ([@B36]), Canada                                    CP                 \<3 months                48.7 days ± 23.6[°](#TN2){ref-type="table-fn"}        Fever                                                                   257                       Low
  Houten et al. ([@B37]), Netherlands                                CP                 2--60 months              21 months ± 16[°](#TN2){ref-type="table-fn"}          Fever and LRTI symptoms or without source                               577                       Moderate
  Irwin et al. ([@B38]), UK                                          CP                 \<16 years                2.4 years (0.9--5.7)                                  Fever and blood tests                                                   1101                      High
  Isaacman et al. ([@B39]), US                                       CR                 3--36 months              18 months ± 9.8[°](#TN2){ref-type="table-fn"}         Fever without source in a GED[¥](#TN3){ref-type="table-fn"}             79                        Low
                                                                                                                  16.3 months ±8.8[°](#TN2){ref-type="table-fn"}        Fever without source in a PED[¥](#TN3){ref-type="table-fn"}             498                       
  Iyer et al. ([@B40]), US                                           RCT                2--24 months              ±75% 6--24 months                                     Fever                                                                   700                       Moderate
  Jain et al. ([@B41]), US                                           CP                 \<18 years                NR                                                    Fever                                                                   19075                     High
  Khine et al. ([@B42]), US                                          CR                 3--36 months              15.2 months ±8.7[°](#TN2){ref-type="table-fn"}        Reported fever in GED                                                   237                       Moderate
                                                                                                                                                                                                                                                                          
                                                                                        3--36 months              16.6 months ±9.1[°](#TN2){ref-type="table-fn"}        Reported fever in PED                                                   224                       
  Kilic et al. ([@B43]) Turkey                                       CSr                3--140 months             41.2 months ±31[°](#TN2){ref-type="table-fn"}         Asthma, croup, Bronchiolitis                                            2544                      Low
  Kornblith et al. ([@B44]), US                                      CSr                0--18 years               ± 56% 1--5 years                                      ARTI                                                                    6461                      High
  Kronman et al. ([@B45]), US                                        CSr                1--18 years               50--60% 1--5 years                                    CAP                                                                     266.000                   High
  Lacroix et al. ([@B46]), France                                    RCT                7 days−36 months          3.4 months (1.5--10.4)                                Fever without source                                                    271                       High
                                                                                                                  4.8 months (1.7--10.4)                                                                                                                                  
  Linder et al. ([@B47]), US                                         CSr                3--17 years               45% 6--11 years                                       Sore throat                                                             6955                      High
  Li-Kim-Moy et al. ([@B48]), Australia                              CR                 0 ≤ 18 years              3.1 years (1.1--7.4)                                  Lab proven influenza                                                    301                       Moderate
  Manzano et al. ([@B49]), Canada                                    RCT                1--36 months              12 ± 8 months[°](#TN2){ref-type="table-fn"}           Fever                                                                   384                       High
                                                                                                                  12 ± 8 months[°](#TN2){ref-type="table-fn"}                                                                                                             
  Massin et al. ([@B50]) Belgium                                     CP                 1--36 months              13.8 months ±9.7[°](#TN2){ref-type="table-fn"}        Fever without source [¥](#TN3){ref-type="table-fn"}                     376                       Moderate
                                                                                                                                                                                                                                                                          
  McCaig et al. ([@B51]), US                                         CSr                3 months−2 years          NR                                                    Fever and BC (discharged)                                               5.4% of all ED visits     Low
  McCormick et al. ([@B52]), US                                      RCT                6--72 months              ±60% \< 1 years                                       AOM                                                                     209                       Moderate
  Murray et al. ([@B53]), US                                         CP                 \<56 days                 36 days ± 13.8                                        Fever                                                                   520                       Low
  Nelson et al. ([@B54]), US[^\*^](#TN1){ref-type="table-fn"}        CP                 3 months−18 years         2.8 years (4.4)                                       Pneumonia                                                               3220                      High
  Nibhanipudi et al. ([@B55]), US[^\*^](#TN1){ref-type="table-fn"}   CP                 2--17 years               5.72 years ± 0.38[°](#TN2){ref-type="table-fn"} (m)   AOM                                                                     100                       Low
                                                                                                                  7.41 years ± 0.75[°](#TN2){ref-type="table-fn"} (f)                                                                                                     
  Ochoa et al. ([@B56]), Spain                                       CSr                0--18 years               ±3 years (1 months−18 years)                          ARTI                                                                    6249                      High
  Ong et al. ([@B57]), US                                            CP                 All ages (20% child)      33 years                                              URTI                                                                    272                       Moderate
  Özkaya et al. ([@B58]), Turkey                                     CSp                3--14 years               5.7 years ± 3.4[°](#TN2){ref-type="table-fn"}         Influenza like illness                                                  97                        Low
                                                                                                                  4.25 years ± 2.02                                                                                                                                       
  Ouldali et al. ([@B59]), France                                    qRCT               \<18 years                1.6 years (0.7--3.6)                                  ARTI                                                                    196.062                   High
                                                                                                                  1.7 years (0.7--3.7)                                                                                                                                    
  Planas et al. ([@B60]), Spain                                      CP                 \<3 months                35 days ± 31[°](#TN2){ref-type="table-fn"}            Fever without source and BC (admitted) [¥](#TN3){ref-type="table-fn"}   381                       Moderate
  Ploin et al. ([@B61]), France                                      CP                 \<36 months               NR                                                    Fever during influenza season                                           538                       Moderate
  Poehling et al. ([@B62]), US                                       RCT                \<5 years                 NR                                                    Fever or ARS during influenza season                                    305                       Moderate
  Shah et al. ([@B63]), US                                           CSr                1--18 years               ± 63% 1--4 years                                      Fever and cough or respiratory distress                                 3466                      Moderate
  Sharma et al. ([@B64]), US                                         CSr                2--24 months              9 months [°](#TN2){ref-type="table-fn"}               Fever and positive influenza test                                       72                        Low
  Spiro et al. ([@B65]), US                                          RCT                6--35 months              17.3 months[°](#TN2){ref-type="table-fn"}             Fever or ARS                                                            681                       High
                                                                                                                  17.2 months[°](#TN2){ref-type="table-fn"}                                                                                                               
  Spiro et al. ([@B66]), US                                          RCT                6 months−12 years         3.2 years                                             AOM                                                                     283                       High
                                                                                                                  3.6 years                                                                                                                                               
  Trautner et al. ([@B67]), US                                       CSp                \<18 years                17 months (11--25 months)                             Hyperpyrexia                                                            103                       Moderate
  de Vos-Kerkhof et al. ([@B68]), Netherlands                        RCT                1 months−16 years         1.7 years (0.8--3.9)                                  Fever                                                                   439                       Moderate
                                                                                                                  2.0 years (1.0--4.2)                                                                                                                                    
  Waddle and Jhaveri, ([@B69]), US                                   CSr                3--36 months              17 months ± 11[°](#TN2){ref-type="table-fn"}          FWS and BC                                                              423                       Low
                                                                                                                  15 months ± 10[°](#TN2){ref-type="table-fn"}                                                                                                            
  Wheeler et al. ([@B70]), US                                        CP                 ≤ 18 years                3 years (1 months−20 years)                           Viral infections                                                        144                       Moderate

*CC, case control; CP, prospective cohort; CR, retrospective cohort; CS, cross-sectional; r, retrospective; p, prospective*.

*Estimated/calculated from numbers in article*.

*Mean age is given, median age was not reported*.

*Fever without source: as defined in corresponding study*.

Sixteen studies (29%) were considered as high quality and 17 (30%) were considered low quality. In general, observational studies did not describe sufficiently how sample size was approximated. Almost all high quality studies, except one ([@B3]), used antibiotic prescriptions as a primary outcome.

Antibiotic prescriptions in febrile children and specific conditions
--------------------------------------------------------------------

Table [2](#T2){ref-type="table"} presents the antibiotic prescriptions among the five diagnostic groups we distinguished. Sixteen out of 26 descriptive studies focused on febrile children in general, one paper specifically addressed acute otitis media (AOM) ([@B30]), two pneumonia ([@B45], [@B63]), four other respiratory infections (RTI other)([@B19], [@B23], [@B43], [@B57]), and one urinary tract infections (UTI)([@B32]). One paper on febrile children also provide separate numbers for pneumonia and UTI ([@B3]) and one for AOM ([@B61]). Two additional papers focused on respiratory infections and provided separate numbers for pneumonia, AOM and RTI other ([@B44], [@B56]).

###### 

Antibiotic prescription per diagnosis.

  **Reference, Country**                                             **Age group/ inclusion**   **Median (IQR) or Mean age ± SD**                 **Inclusion criteria**                                                  **N children included**   **N antibiotics, % of study population[^ł^](#TN7){ref-type="table-fn"}**
  ------------------------------------------------------------------ -------------------------- ------------------------------------------------- ----------------------------------------------------------------------- ------------------------- --------------------------------------------------------------------------
  **FEVER IN GENERAL**                                                                                                                                                                                                                              
  Bustinduy et al. ([@B28]), UK                                      \<16 years                 2 years (1--4 years)                              Fever or reported fever                                                 1097                      44%
  Colvin et al. ([@B31]), US                                         2--36 months               8.0 months                                        Fever without source [¥](#TN6){ref-type="table-fn"}                     75                        45%
  Craig et al. ([@B3]), Australia                                    \<6 years                  ± 60% \< 24 months                                Fever                                                                   15.781                    27%
  Galetto Lacour et al. ([@B35]), Switzerland                        7 days−36 months           11 months[^\*^](#TN4){ref-type="table-fn"}        Fever without source [¥](#TN6){ref-type="table-fn"}                     124                       62.1%
  Galetto-Lacour et al. ([@B35]), Switzerland                        7 days−36 months           7.2 months (0.4--31.1) 9.7 months (0.7--34)       Fever without source [¥](#TN6){ref-type="table-fn"}                     99                        71%
  Goldman et al. ([@B36]), Canada                                    \<3 months                 48.7 days ± 23.6[°](#TN5){ref-type="table-fn"}    Fever                                                                   257                       55%
  Houten et al. ([@B60]), Netherlands                                2--60 months               21 months ± 16[°](#TN5){ref-type="table-fn"}      Fever and LRTI symptoms or without source                               577                       39%
  Isaacman et al. ([@B39]), US                                       3--36 months               18 months ± 9.8[°](#TN5){ref-type="table-fn"}     Fever without source in a GED[¥](#TN6){ref-type="table-fn"}             79                        39.2%
                                                                                                16.3 months ±8.8[°](#TN5){ref-type="table-fn"}    Fever without source in a PED[¥](#TN6){ref-type="table-fn"}             498                       16.7%
  Khine et al. ([@B42]), US                                          3--36 months               15.2 months ±8.7[°](#TN5){ref-type="table-fn"}    Reported fever in GED                                                   237                       41%
                                                                     3--36 months               16.6 months ±9.1[°](#TN5){ref-type="table-fn"}    Reported fever in PED                                                   224                       27%
  Massin et al. ([@B50]), Belgium                                    1--36 months               13.8 months ± 9.7[°](#TN5){ref-type="table-fn"}   Fever without source [¥](#TN6){ref-type="table-fn"}                     376                       15%
  Ploin et al. ([@B61]), France                                      \<36 months                NR                                                Fever during influenza season                                           538                       34.8%
  **FEVER AND SELECTION ON ADDITIONAL TESTING OR CHARACTERISTICS**                                                                                                                                                                                  
  Irwin et al. ([@B38]), UK                                          \<16 years                 2.4 years (0.9--5.7)                              Fever and blood tests                                                   1101                      855, 78%
  Trautner et al. ([@B67]), US                                       \<18 years                 17 months (11--25 months)                         Hyperpyrexia                                                            103                       46, 61.3%
  Brauner et al. ([@B26]), Israel                                    3--36 months               NR                                                Fever and complete blood count                                          292                       148, 50.7%
  Planas et al. ([@B60]), Spain                                      \<3 months                 35 days ± 31[°](#TN5){ref-type="table-fn"}        Fever without source and BC (admitted) [¥](#TN6){ref-type="table-fn"}   381                       281, 73.8[^\*^](#TN4){ref-type="table-fn"}%
  **AOM**                                                                                                                                                                                                                                           
  Coco et al. ([@B30]), US                                           \<12 years                 ± 2 years[^\*^](#TN4){ref-type="table-fn"}        AOM                                                                     8325                      82.6%
  Kornblith et al. ([@B44]), US                                      0--18 years                ± 56% 1--5 years                                  AOM                                                                     647                       88%
  Ochoa et al. ([@B56]), Spain                                       0--18 years                ±3 years (1 months−18 years)                      AOM                                                                     821                       93%
  Ploin et al. ([@B61]), France                                      \<36 months                NR                                                Fever during influenza season                                           18                        89%
  **PNEUMONIA**                                                                                                                                                                                                                                     
  Craig et al. ([@B3]) Australia                                     \<6 years                  ± 60% \< 24 months                                Pneumonia                                                               533                       69%
  Kornblith et al. ([@B44]), US                                      0--18 years                ± 56% 1--5 years                                  Pneumonia                                                               657                       86%
  Kronman et al. ([@B45]), US                                        1--18 years                50--60% 1--5 years                                CAP                                                                     266.000                   86.1%
  Ochoa et al. ([@B56]), Spain                                       0--18 years                ±3 years (1 months−18 years)                      Pneumonia                                                               288                       93%
  Shah et al. ([@B63]), US                                           1--18 years                ± 63% 1--4 years                                  Pneumonia                                                               347                       82%
  **RTI OTHER**                                                                                                                                                                                                                                     
  Ahmed et al. ([@B19]), US                                          0--18 years                NR                                                URTI                                                                    321                       43%
  Benin et al. ([@B23]), US                                          3--18 years                8.7 years (6--13)                                 Diagnosis pharyngitis                                                   391                       23%
  Kilic et al. ([@B43]), Turkey                                      3--140 months              41.2 months ±31[°](#TN5){ref-type="table-fn"}     Asthma, croup, Bronchiolitis                                            2544                      16.6%
  Kornblith et al. ([@B44]), US                                      0--18 years                ± 56% 1--5 years                                  URTI                                                                    5157                      36%
  Ochoa et al. ([@B56]), Spain                                       0--18 years                ±3 years (1 months−18 years)                      URTI                                                                    5140                      51%
  Ong et al. ([@B57]), US                                            All ages (20% child)       33 years                                          URTI                                                                    272                       83, 31%
  **UTI**                                                                                                                                                                                                                                           
  Copp et al. ([@B32]), US                                           \<18 years                 ±6 years[^\*^](#TN4){ref-type="table-fn"}         UTI                                                                     1828                      70%
  Craig et al. ([@B3]), Australia                                    \<6 years                  ± 60% \< 24 months                                Fever                                                                   543                       66%

*Estimated/calculated from numbers in article*.

*Mean age is given, median age was not reported*.

*Fever without source: as defined in corresponding study*.

*Antibiotic prescription is given for reported age group, except for Ong et al ([@B57]) antibiotic use for all ages is given*.

### Fever

Sixteen out of 26 studies focused on febrile children in general, seven of them selected children based on fever without source; five included febrile children based on additional testing (Table [2](#T2){ref-type="table"}). In studies of general febrile populations only, antibiotic prescriptions ranged from 15 to 71% ([@B3], [@B31], [@B35], [@B36], [@B39], [@B42], [@B50], [@B61], [@B71]). The lowest prescriptions (15%) came from a study on parenteral empirical antibiotics only ([@B50]). Study quality did not influence antibiotic prescription rate.

Three high quality, six moderate quality and two low quality studies reported on SBI rate, which ranged from 7 to 41% (Figure [2](#F2){ref-type="fig"}) ([@B3], [@B26], [@B35]--[@B38], [@B42], [@B44], [@B50], [@B60], [@B71]). As the SBI rate in Khine et al. ([@B42]) is similar to antibiotic prescriptions, one may question how SBI is defined. Massin et al. ([@B50]) reports on parenteral antibiotics only and may not represent antibiotic prescription in total. Focusing on the remaining eight studies, we observe a trend toward higher antibiotic prescriptions with higher rates of SBI, although not significant.

![Serious bacterial infection rate and antibiotic prescriptions per study. ![](fped-06-00260-i0001.jpg) *High/Moderate quality*, ![](fped-06-00260-i0002.jpg) *High/Moderate quality, outlier*, ![](fped-06-00260-i0003.jpg) *Low quality*, ![](fped-06-00260-i0004.jpg) *Low quality, outlie*.](fped-06-00260-g0002){#F2}

In the studies on fever in general, we observed a higher prescriptions in children under the age of one (45 to 71%; weighted mean 58%), compared to older ones (prescriptions of 17 to 44%; weighted mean 28%), independent of study quality (Figure [3](#F3){ref-type="fig"}) ([@B3], [@B28], [@B31], [@B35]--[@B37], [@B39], [@B42], [@B50], [@B71]).

![Antibiotic prescriptions arranged on age in children with fever. Studies are arranged by age, i.e., left represents younger children to right (older ages). Light bars represent studies with a low quality.](fped-06-00260-g0003){#F3}

None of the studies on febrile children in general compared antibiotic prescriptions between countries. In the eleven studies ([@B3], [@B28], [@B31], [@B35]--[@B37], [@B39], [@B42], [@B50], [@B61], [@B71]) on children with fever in general (without additional testing), the highest prescriptions were reported in a Swiss study (71%) ([@B35]) and the lowest in a study originating from the US (17%) ([@B39]). The three studies originating from the US reported antibiotic prescription between 39--45% ([@B31], [@B39], [@B42]); for the two Swiss studies this varied from 62 to 71%, although originating from the same hospital ([@B35], [@B71]).

### Antibiotic prescription for specific diagnoses

Four studies provided data for antibiotic prescription in AOM, ranging from 88--93%. We could not determine influences of age on prescriptions. Five studies reported on antibiotic prescription in pneumonia, ranging from 69 to 93%. The study with the lowest prescription ([@B3]) included children \<6 years only compared to the other four (including children in the range of 1-18 years). Antibiotic prescription in RTI other (6 studies) varied on a broader range from 17 to 51%, but could not be related to age. Only two studies provided information on antibiotic prescription in UTI, ranging from 66 to 70%.

### Type of antibiotic prescription

Nine out of 26 (35%) studies \[two high quality ([@B30], [@B56])\] reported on antibiotic type (Figure [4](#F4){ref-type="fig"}). Six studies addressed respiratory tract infections ([@B19], [@B30], [@B43], [@B56], [@B57], [@B63]) and five were conducted in the US ([@B19], [@B30], [@B32], [@B57], [@B63]). We did not observe a predominance for one antibiotic type for a specific diagnosis or country; amoxicillin was always reported. Studies describing cephalosporin use (*n* = 7) included both second or third generations.

![Type of antibiotic as percentage of total antibiotics prescribed per study. \*As defined in article. Ahmed et al. ([@B19]): not specified; Copp et al. ([@B32]): nitrofurantoin and others are not specified antibiotics. Coco et al. ([@B30]): not specified. Ochoa et al. ([@B56]): trimethoprim/sulfamethoxazole, clindamycin, fosfomycin, rifampin, trimethoprim, topical use and others are not specified. Ong et al. ([@B57]): trimethoprim/sulfamethoxazole; Shah et al. ([@B63]): not specified. ^∧^Calculated from article as percentage of total antibiotics, in article given as percentage of cases.](fped-06-00260-g0004){#F4}

### Prescribing physician

Five ([@B39], [@B42], [@B47], [@B63], [@B72]) out of seven studies \[three high quality studies ([@B44], [@B47], [@B66])\], reported significant lower antibiotic prescriptions by pediatric emergency physicians compared to general emergency physicians (Table [3](#T3){ref-type="table"}). Two addressed young children with fever without source ([@B39], [@B42]), and five addressed older children with respiratory tract infections ([@B19], [@B44], [@B47], [@B63], [@B65]).

###### 

Difference in antibiotic prescription between general physicians and pediatric physicians.

  **Reference, Country**                                       **N Antibiotics given by GEMP/N seen by GEMP % antibiotics**   **N antibiotics given by PEMP/N seen by PEMP % antibiotics**   **Inclusion criteria**
  ------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------------------------- ------------------------
  Isaacman et al. ([@B39]), US                                 37/79, 39%                                                     83/498, 17%                                                    FWS
  Khine et al. ([@B42]), US                                    97/237, 41%                                                    61/224, 27%                                                    FWS
  Ahmed et al. ([@B19]), US                                    NR/238, 32%                                                    NR/345, 17%                                                    URTI
  Kornblith et al. ([@B44]), US                                NR, 46%                                                        NR, 42%                                                        ARTI
  Shah et al. ([@B63]), US                                     2946, 50%                                                      520, 35%                                                       Febrile RTI
  Linder et al. ([@B47]), US                                   NR, 60%                                                        NR, 47%                                                        Sore throat
  Spiro et al. ([@B65]), US[^\*^](#TN8){ref-type="table-fn"}   NR, 30%                                                        NR, 26%                                                        Fever/ARS

*No significant statistical difference was found*.

$High\ quality\ study.$

$Moderate\ quality\ study.$

$Low\ quality\ study.$

The effect of interventions on antibiotic prescription
------------------------------------------------------

Nine out of 27 studies on interventions for antibiotic prescription (32%) reported about rapid viral testing ([@B22], [@B24], [@B25], [@B27], [@B33], [@B40], [@B58], [@B62], [@B64]), four about delayed antibiotic prescription in acute otitis media ([@B29], [@B34], [@B52], [@B66]), six about guideline/management strategies ([@B20], [@B21], [@B41], [@B53], [@B59], [@B68]), four about laboratory tests ([@B22], [@B46], [@B47], [@B49]) and five using other interventions (Table [4](#T4){ref-type="table"}). In fourteen studies (50%) a significant reduction in antibiotic use was found.

###### 

Influence of intervention on antibiotic prescription.

  **Reference, Country**                                              **Median (IQR) or Mean age ± SD ¥**                    **Intervention**                                           **Inclusion**                          **N intervention total, % AB**               **N controls total, % AB**
  ------------------------------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------- -------------------------------------- -------------------------------------------- ----------------------------------------------
  **FEVER IN GENERAL**                                                                                                                                                                                                                                                      
  Aronson et al. ([@B21]), US                                         46 days (37--53)                                       CPG recommending ceftriaxone compared to no CPG            Fever                                  306, 64.1%[^∧^](#TN9){ref-type="table-fn"}   1.304, 11.7%[^∧^](#TN9){ref-type="table-fn"}
                                                                      45 days (37--53)                                                                                                                                                                                      
                                                                                                                             CPG recommending against ceftriaxone compared to no CPG                                           313, 10.9%[^∧^](#TN9){ref-type="table-fn"}   1.304, 11.7%[^∧^](#TN9){ref-type="table-fn"}
  Jain et al. ([@B41]), US                                            NR                                                     Physician feedback through scorecards                      Fever                                  8.961, 10.8%                                 1.0114, 12%
  Lacroix et al. ([@B46]), France                                     3.4 months (1.5--10.4)                                 Lab Score                                                  FWS                                    131, 41.2%                                   140, 42.1%
                                                                      4.8 months (1.7--10.4)                                                                                                                                                                                
  Manzano et al. ([@B49]), Canada                                     12 ± 8 months[°](#TN1){ref-type="table-fn"}            PCT testing                                                Fever                                  192, 25%                                     192, 28%
                                                                      12 ± 8 months[°](#TN1){ref-type="table-fn"}                                                                                                                                                           
  Murray et al. ([@B53]), US                                          36 days ± 13.8                                         Implementation of a clinical pathway                       Fever                                  296, 69%                                     224, 72%
  de Vos-Kerkhof et al. ([@B68]), Netherlands                         1.7 years (0.8--3.9)                                   Clinical decision model                                    Fever                                  219, 35.6%                                   220, 41.8%
                                                                      2.0 years (1.0--4.2)                                                                                                                                                                                  
  **(SUSPICION OF) BACTERIAL INFECTIONS**                                                                                                                                                                                                                                   
  Nelson et al. ([@B54]), US [^\*^](#TN10){ref-type="table-fn"}       2.8 years (4.4)                                        Antibiotic prescription rate before and after CXR result   Pneumonia                              1610, 23%                                    1610, 7%
  de Vos-Kerkhof et al. ([@B68]), Netherlands                         1.8 (0.9--4.1)                                         Clinical decision model                                    Fever and SBI                          192, 22.9%                                   192, 27.1%
  Waddle and Jhaveri ([@B69]), US                                     17 months ± 11[°](#TN11){ref-type="table-fn"}          PCV7                                                       FWS and BC                             275, 57.2%                                   148, 60.8%
                                                                      15 months ± 10[°](#TN11){ref-type="table-fn"}                                                                                                                                                         
  **INFLUENZA**                                                                                                                                                                                                                                                             
  Blaschke 2014 ([@B25]), US^◇^                                       53% \< 18 years                                        Rapid viral testing (positive/negative RVT)                RVT performed                          NR, 11%                                      NR, 47%
  Benito-Fernández et al. ([@B24]), Spain                             6.86 months ± 6.3[°](#TN11){ref-type="table-fn"}       Rapid viral testing (positive/negative RVT)                Fever without source                   84, 0%                                       122, 38.5%
                                                                      6.55 months ± 6.8[°](#TN11){ref-type="table-fn"}                                                                                                                                                      
  Bonner et al. ([@B27]), US                                          NR                                                     Rapid viral testing (RVT /no RVT)                          Influenza positive                     96, 7%                                       106, 25%
  Doan et al. ([@B33]), Canada                                        15 months (3--36)                                      Rapid viral testing (POCT/standard testing)                Acute respiratory symptoms             89, 18%                                      110, 21%
                                                                      14 months (4--34)                                                                                                                                                                                     
  Iyer et al. ([@B40]), US                                            ±75% 6--24 months                                      Rapid viral testing (RVT/ no RVT)                          Fever                                  345, 25.3%                                   355, 30.5%
  Li-Kim-Moy et al. ([@B48]), Australia                               3.1 years (1.1--7.4)                                   Rapid viral testing (POCT/standard testing)                Lab proven influenza                   236, 33%                                     65, 54%
  Özkaya et al. ([@B58]), Turkey                                      5.7 years ± 3.4[°](#TN11){ref-type="table-fn"}         Rapid viral testing (RVT /no RVT)                          Influenza-like illness                 50, 58%                                      47, 100%
                                                                      4.25 years ± 2.02[°](#TN11){ref-type="table-fn"}                                                                                                                                                      
  Poehling et al. ([@B62]), US                                        NR                                                     Rapid viral testing (RVT/no RVT)                           Fever or ARS during influenza season   135, 32%                                     170, 29%
  Sharma et al. ([@B64]), US                                          9 months[°](#TN11){ref-type="table-fn"}                Rapid viral testing (RVT /no RVT)                          Fever and positive influenza test      47, 2%                                       25, 24%
  **AOM**                                                                                                                                                                                                                                                                   
  Chao et al. ([@B29]), US                                            5.01 years (3.67--6.68)                                Delayed prescription with and without prescription         AOM                                    100, 19%                                     106, 46%
                                                                      3.73 years (2.82--5.75)                                                                                                                                                                               
  Fischer et al. ([@B34]), US                                         68% 2--6 years                                         Wait-and-see prescription in AOM                           AOM                                    144, 27%                                     N.A.
  McCormick et al. ([@B52]), US                                       ±60% \< 1 years                                        Wait-and-see prescription in AOM                           AOM                                    100, 34%                                     109, 100%
  Nibhanipudi et al. ([@B55]), US[^\*^](#TN10){ref-type="table-fn"}   5.72 years ± 0.38[°](#TN11){ref-type="table-fn"} (m)   WBC \>15.000 or WBC \< 15.000                              AOM                                    93, 3%                                       7, 100%
                                                                      7.41 years ± 0.75[°](#TN11){ref-type="table-fn"} (f)                                                                                                                                                  
  Spiro et al. ([@B66]), US                                           3.2 years                                              Wait-and-see prescription in AOM                           AOM                                    138, 38%                                     145, 87%
                                                                      3.6 years                                                                                                                                                                                             
  **RTI Other**                                                                                                                                                                                                                                                             
  Angoulvant et al. ([@B20]), France                                  17 months (7--40)                                      Implementing guidelines                                    ARTI                                   NR, 21%                                      NR, 32.1%
  Ayanruoh et al. ([@B22]), US                                        NR                                                     Rapid streptococcal testing                                Clinical diagnosis of pharyngitis      6.557, 22.45%                                1.723, 41.38%
  Linder et al. ([@B47]), US                                          45% 6--11 years                                        GABHS testing in sore throat                               Sore throat                            NR, 48%                                      NR, 51%
  Ouldali et al. ([@B59]), France                                     1.6 years (0.7--3.6)                                   Implementation of national guidelines                      ARTI                                   134.450,−28.4%                               61.612
                                                                      1.7 years (0.7--3.7)                                                                                                                                                                                  
  Spiro et al. ([@B65]), US                                           17.3 months[°](#TN11){ref-type="table-fn"}             Tympanometry for reduction antibiotics in AOM              Fever or ARS                           341, 28.8%                                   340, 26.8%
                                                                      17.2 months[°](#TN11){ref-type="table-fn"}                                                                                                                                                            
  Wheeler et al. ([@B70]), US                                         3 years (1 months−20 years)                            Videotape in waiting room                                  Viral infections                       71, 4.2%                                     73, 6.8%

*Only parenteral antibiotic prescription rate is given. Highlighted studies indicate studies with significant results*.

*Estimated/calculated from numbers in article*.

*Mean age given, median age not reported*.

### Interventions for AOM

Interventions with a significant effect on antibiotic reduction were guidelines and the wait-and-see prescription in acute otitis media (AOM). For this latter a significant reduction was found in four articles (three of them with moderate to high quality) ([@B29], [@B34], [@B52], [@B66]).

### Viral testing intervention

Most studies on interventions for reduction of antibiotic prescription addressed rapid viral testing for influenza (RVT, *n* = 9). Fewer antibiotics were prescribed when the RVT is positive ([@B24], [@B25], [@B27], [@B64]), although not confirmed by studies on the impact of RVT use vs. not using RVT in the ED ([@B27], [@B40], [@B58], [@B62]). Only one low quality study reported a significant difference for this topic ([@B58]). The use of point-of-care testing above testing on indication had only significant benefit in children with proven influenza ([@B33], [@B48]). One study reported reduced length of stay, but no effect on antibiotic prescription ([@B48]).

### Other interventions

Three high quality studies showed a significant reduction in antibiotic prescription by a guideline for lower respiratory infections or infants with fever ([@B20], [@B21], [@B41]). Among two articles on streptococcal A testing, the article with the highest quality didn\'t find a significant reduction ([@B22], [@B47]). Introduction of a clinical pathway for young febrile infants showed reduced time to first antibiotic dose, but did not evaluate the effect on antibiotic prescription itself ([@B53]). The use of chest radiographs in particular reduces antibiotics in children with low clinical suspicion of pneumonia ([@B54]). For all other interventions no significant reduction was found on antibiotic prescription ([@B46], [@B49], [@B65], [@B69], [@B70]).

Discussion {#s4}
==========

Interpretation of main findings
-------------------------------

We observed a highly variable reported antibiotic prescriptions in children presenting to a general or pediatric ED in the five major groups of diagnosis. Studies on a specific diagnosis, such as AOM, pneumonia, or UTI report higher antibiotic prescriptions. However, studies are too heterogeneous to study true effects of determinants. Strong evidence was found for watchful waiting in AOM and implementation of guidelines for fever or respiratory infections to reduce antibiotic use in the ED. Intervention studies report mostly on rapid viral testing for influenzae (RVT) to reduce antibiotic prescription, but its effect is controversial.

It is important to note that the high variability in antibiotic prescription observed in our systematic review differ from reported antibiotic prescriptions from literature, or websites ([@B12], [@B73]). However, these numbers are based on national or local registries and include in-hospital patients, not reflecting our interest on use of antibiotics in ED settings. Next, not all countries are represented in our systematic review and only Switzerland, USA are represented by more than one study. For the latter two, however we observed high variability in antibiotic prescription within studies of the same country. Even within studies focusing on similar group of diagnoses, we observed a large heterogeneity in their way of patient selection and their type of febrile illness. Therefore, we think these antibiotic prescriptions cannot be considered to be representative for the general population of febrile children in a country.

Limited evidence was found for age effects on antibiotic prescriptions, potentially due to age distribution among study populations. Infants below 2 months are underrepresented in our review. From community studies, we know that pre-school children are more frequently exposed to antibiotic therapy ([@B13]).

After exclusion of two outlier studies given their patient selection and outcome definition ([@B42], [@B50]), we observed in studies on children with fever a trend toward higher antibiotic prescriptions in studies with higher SBI rates is noticeable. This, however, only explains some variation in antibiotic prescription.

Similar to studies in primary care, watchful waiting intervention seems highly effective for reducing antibiotic use in AOM at the ED ([@B74]). Results however are limited to patients above the age of 6 months that did not appear toxic and it is questionable if the study populations were large enough to detect serious adverse outcomes such as meningitis. Although the most frequently studied intervention, rapid viral testing for influenza has no additional effect above testing on indication and controversial evidence was found for its effect. Effects of guidelines are seen in two well-defined groups (respiratory infections or young febrile infants) and including a well-defined implementation plan. Implementation of a clinical decision model to reduce antibiotic prescriptions was only tested in a tertiary pediatric university ED and antibiotic reduction was not a primary outcome of this study ([@B17]). All other interventions are not (yet) proven to be effective for reducing the antibiotic prescriptions in children on the ED. Overall the evidence to reduce antibiotic prescription in the emergency department remains limited. We observed a general association between antibiotic prescription and the type of prescriber, i.e., pediatricians prescribe less antibiotics than general physicians may suggest that guideline implementation could be most effective in hospitals with general physicians treating children in the ED.

Limitations
-----------

The quality of the studies that reported about fever in general was low to moderate, with only one high quality study ([@B3]). Specific drawbacks of study design are included in the MINOR assessment as a measure of quality. The use of MINORS in combination with the study population and study aim helps to increase the reproducibility of this review and made it possible to compare the different levels of evidence ([@B16]). Most studies did not reported on missing values regarding antibiotic prescription, which could lead to an underestimation of antibiotic prescriptions. In a substantial part of the included papers, antibiotic prescription was not the primary outcome. This may explain some diversity in antibiotic prescriptions, although this was partially corrected for in the quality assessment.

This systematic review focuses on prescription of antibiotics in the ED setting. In many European countries, antibiotics are available as over the counter drugs as well ([@B75]). This issue is not accounted for by any of the articles, which may lead to a general underestimation of the antibiotic use.

Unfortunately, we observed a large heterogeneity of the studies or had only 1 study per diagnosis group, hampering meta-analysis. Most heterogeneity is caused by specific patient selection (age, setting), by study design (intervention vs. observational cohort study). This also applies to the population of febrile children \<36 months that constitute the majority of ED attendances.

Future research recommendations
-------------------------------

To validly estimate baseline antibiotic prescriptions in children with fever presenting to the emergency department we need observational studies including the general spectrum of febrile children. Being able to determine influences of antibiotic prescription, we should address geographical and cultural influences, differences in setting, adherence area, general patient characteristics, and descriptors of illness severity. Insight in these determinants may help to define targets for intervention to reduce antibiotic prescriptions. Next, this information will contribute to valid power calculations for intervention studies and to generalize effects to other settings.

Conclusion {#s5}
==========

A summary of studies on antibiotic prescription in the 5 main diagnostic groups at the ED did not yield uniform outcomes. There seems to be a trend toward higher antibiotic prescriptions in younger children and for diagnoses that are more often related to bacterial infections. Delayed antibiotic prescription in children with acute otitis media and guidelines for fever/LRTI seem useful to reduce antibiotic prescriptions at the ED. However no strict conclusions can be drawn on the basis of this review because of the large heterogeneity of type of studies and included populations. This means that there is still a gap in knowledge on the determining factors that influence antibiotic prescription in febrile children presenting to the ED. A multicentre study including a wide range of countries on a general population of febrile children would be recommended to provide a valid baseline of antibiotic prescriptions in general, and influencing factors that identify targets for future interventions.
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Click here for additional data file.

AB

:   antibiotic(s)

AOM

:   acute otitis media

ARS

:   acute respiratory symptoms

ARTI

:   acute respiratory tract infection

BC

:   blood culture

CAP

:   community acquired pneumonia

CC

:   case control study

CI

:   confidence interval

CP

:   cohort study prospective

CR

:   cohort study retrospective

CS

:   cross sectional study

CSF

:   cerebrospinal fluid

d

:   days

ED

:   emergency department

EL

:   extreme leukocytosis

FWS

:   fever without source

GED

:   general emergency department

GEMP

:   general emergency medicine physician

ILI

:   influenza-like illness

ML

:   moderate leukocytosis

mo

:   months

NR

:   not reported

NS

:   not specified

PED

:   pediatric emergency department

PEMP

:   pediatric emergency medicine physician

qRCT

:   quasi-randomized controlled trial

RCT

:   randomized controlled trial

reg

:   registration

RIDT

:   rapid influenza diagnostic tests

RST

:   rapid streptococcal test

RVT

:   rapid viral testing

SBI

:   serious bacterial infection

SD

:   standard deviation

T

:   temperature

URTI

:   upper respiratory tract infection

UTI

:   urinary tract infection

y

:   years.
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